Results 21 to 30 of about 1,201,269 (362)

Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort

BMC Cancer, 2022
Background There is no clear consensus on the benefits of adjuvant chemotherapy for tumor-node-metastasis (TNM) stage T1 (T1N0M0) breast cancer (BC). Our study investigated the effects of adjuvant chemotherapy on T1N0M0 BC patients.
Kaiwen Shen, Longdi Yao, Jingyuan Zhu, Ximing Gu, Jie Wang, Wei Qian, Zhijian Zheng, Deyuan Fu, Song Wu   +8 more
doaj   +1 more source

Adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: updated results of the Seoul National university hospital experience

International Brazilian Journal of Urology, 2015
Objectives: The objective of this study was to update the long-term outcome in the treatment of locally advanced upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU) regarding the role of adjuvant chemotherapy.
Hyung Suk Kim, Joong Sub Lee, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku   +5 more
doaj   +1 more source

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

New England Journal of Medicine, 2005
BACKGROUND We present the combined results of two trials that compared adjuvant chemotherapy with or without concurrent trastuzumab in women with surgically removed HER2-positive breast cancer.
E. Romond, E. Perez, J. Bryant, V. Suman, C. Geyer, N. Davidson, E. Tan-chiu, S. Martino, S. Paik, P. Kaufman, S. Swain, T. Pisansky, L. Fehrenbacher, L. Kutteh, V. Vogel, D. Visscher, G. Yothers, R. Jenkins, A. Brown, S. Dakhil, E. Mamounas, W. Lingle, P. Klein, J. Ingle, N. Wolmark   +24 more
semanticscholar   +1 more source

Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features.

JAMA Oncology, 2020
Importance Tumor size larger than 4 cm is accepted as an indication for adjuvant chemotherapy in patients with node-negative non-small cell lung cancer (NSCLC). Treatment guidelines suggest that high-risk features are also associated with the efficacy of
R. Pathak, S. Goldberg, M. Canavan, J. Herrin, J. Hoag, Michelle C Salazar, M. Papageorge, T. Ermer, D. Boffa   +8 more
semanticscholar   +1 more source

Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer

BMC Gastroenterology, 2020
Background Biliary tract cancers (BTC) have a poor prognosis even after curative resection because of frequent local and distant recurrences. Therefore, the importance of adjuvant therapy in BTC has been advocated to improve outcomes. However, the choice
Hyera Kim, Mi Hwa Heo, Jin Young Kim
doaj   +1 more source

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

New England Journal of Medicine, 2005
BACKGROUND Trastuzumab, a recombinant monoclonal antibody against HER2, has clinical activity in advanced breast cancer that overexpresses HER2. We investigated its efficacy and safety after excision of early-stage breast cancer and completion of ...
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch, M. Untch, I. Smith, L. Gianni, J. Baselga, R. Bell, C. Jackisch, D. Cameron, M. Dowsett, C. Barrios, G. Steger, C. Huang, M. Andersson, M. Inbar, M. Lichinitser, I. Láng, U. Nitz, H. Iwata, C. Thomssen, C. Lohrisch, T. Suter, J. Rüschoff, T. Suto, V. Greatorex, C. Ward, C. Straehle, E. McFadden, M. Dolci, R. Gelber   +31 more
semanticscholar   +1 more source

Adjuvant Chemotherapy for Stage III Colon Cancer

Cancers, 2020
Simple Summary In patients with stage III colon cancer, adjuvant chemotherapy with a fluoropyrimidine combined with oxaliplatin reduces the risk of recurrence and mortality, with a treatment duration that may be shortened from 6 to 3 months in certain ...
J. Taieb, C. Gallois
semanticscholar   +1 more source

Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer

New England Journal of Medicine, 2018
BACKGROUND The recurrence score based on the 21‐gene breast cancer assay predicts chemotherapy benefit if it is high and a low risk of recurrence in the absence of chemotherapy if it is low; however, there is uncertainty about the benefit of chemotherapy
J. Sparano, R. Gray, D. Makower, K. Pritchard, K. Albain, D. Hayes, C. Geyer, E. Dees, M. Goetz, J. Olson, T. Lively, S. Badve, T. Saphner, L. Wagner, T. Whelan, M. Ellis, S. Paik, W. Wood, P. Ravdin, M. Keane, H. G. Gomez Moreno, P. Reddy, T. Goggins, I. Mayer, A. Brufsky, D. Toppmeyer, V. Kaklamani, J. Berenberg, J. Abrams, G. Sledge   +29 more
semanticscholar   +1 more source

Variations in the body mass index in Brazilian women undergoing adjuvant chemotherapy for breast cancer [PDF]

Revista Brasileira de Ginecologia e Obstetrícia, 2014
PURPOSE:To evaluate variations in the body mass index in patients undergoing adjuvant chemotherapy for breast cancer, and to associate these changes with patient's age and adjuvant chemotherapy regimen.METHODS:We performed a retrospective cohort study in
Marcos Desídérío Ricci, Maria Carolina Formigoni, Lucia Maria Martins Zuliani, Denis Seiiti Aoki, Bruna Salani Mota, José Roberto Filassi, José Roberto Morales Piato, Edmund Chada Baracat   +7 more
doaj   +2 more sources

Adjuvant chemotherapy [PDF]

Cancer, 1978
In this brief presentation, an attempt was made to illustrate why it is not possible to carry over chemotherapeutic trial results from one animal cancer to another or one human cancer to another without corrections for differences in (a) staging, (b) dose response, and (c) tumor regrowth rates.
openaire   +2 more sources